Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment

NCT06199232 · clinicaltrials.gov ↗

NA

Phase

ACTIVE_NOT_RECRUITING

Status

47

Enrollment

OTHER

Sponsor class

Conditions

Liver Metastasis Colon Cancer
ctDNA Genotype
MSS
Failed From Standard Treatment

Interventions

DRUG: HAIC+targeted therapy+PD-1 inhibitor

Sponsor

Peking University